Skip to main content
. 2019 May 1;8(7):3339–3348. doi: 10.1002/cam4.2210

Figure 5.

Figure 5

Patient‐derived conditionally reprogrammed cell lines reveal heterogeneity of chemotherapy response. (A), The growth of CRCs was analyzed via an MTT assay after treatment with various concentrations of gemcitabine over a time‐course (0‐72 hours). YPAC‐16 was more sensitive to the growth‐inhibitory effect of gemcitabine (IC50 <1 μmol/L) than YPAC‐28 (IC50 >100 μmol/L). MTT assay, 3‐(4,5‐dimethylthiazol‐2yl)‐2,5‐diphenyltetrazolium bromide (B) YPAC‐16 which was sensitive to gemcitabine showed better progression free survival than YPAC‐28 (PFS, 238 vs 83 days)